An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Cerebroside-sulfatase (Primary)
- Indications Metachromatic leukodystrophy
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire; Shire Human Genetic Therapies
- 14 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Nov 2018 Planned End Date changed from 1 Oct 2021 to 27 Apr 2023.
- 30 Nov 2018 Planned primary completion date changed from 1 Oct 2021 to 27 Apr 2023.